Cardinal Point Capital Management ULC Takes $1.24 Million Position in UnitedHealth Group Incorporated $UNH

Key Points

• Cardinal Point Capital Management invested $1.24 million in UnitedHealth Group, acquiring approximately 3,966 shares in the second quarter.
• Analysts have mixed ratings on UnitedHealth Group, with JPMorgan and Mizuho raising their price targets significantly, while Weiss Ratings maintained a "sell" rating.
• UnitedHealth Group's quarterly earnings fell short of expectations, with a reported $4.08 EPS against a consensus estimate of $4.45.

Cardinal Point Capital Management ULC bought a new stake in UnitedHealth Group Incorporated (NYSE:UNH - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,966 shares of the healthcare conglomerate's stock, valued at approximately $1,237,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Citizens National Bank Trust Department increased its stake in shares of UnitedHealth Group by 1.0% in the first quarter. Citizens National Bank Trust Department now owns 17,886 shares of the healthcare conglomerate's stock valued at $9,368,000 after buying an additional 170 shares in the last quarter. Caitlin John LLC boosted its holdings in UnitedHealth Group by 14.8% in the first quarter. Caitlin John LLC now owns 862 shares of the healthcare conglomerate's stock valued at $451,000 after acquiring an additional 111 shares during the last quarter. Triumph Capital Management bought a new position in UnitedHealth Group in the second quarter valued at about $1,324,000. Wealth Effects LLC boosted its holdings in UnitedHealth Group by 14.4% in the second quarter. Wealth Effects LLC now owns 4,688 shares of the healthcare conglomerate's stock valued at $1,463,000 after acquiring an additional 591 shares during the last quarter. Finally, Arlington Partners LLC bought a new position in UnitedHealth Group in the second quarter valued at about $2,229,000. 87.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on UNH shares. JPMorgan Chase & Co. raised their price target on UnitedHealth Group from $310.00 to $425.00 and gave the company an "overweight" rating in a report on Thursday, October 9th. Weiss Ratings restated a "sell (d+)" rating on shares of UnitedHealth Group in a report on Wednesday, October 8th. Mizuho raised their target price on UnitedHealth Group from $300.00 to $430.00 and gave the stock an "outperform" rating in a report on Thursday, October 9th. Robert W. Baird restated an "underperform" rating and set a $198.00 target price (down previously from $312.00) on shares of UnitedHealth Group in a report on Thursday, July 31st. Finally, Truist Financial raised their target price on UnitedHealth Group from $310.00 to $365.00 and gave the stock a "buy" rating in a report on Tuesday, September 9th. Eighteen research analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat, UnitedHealth Group presently has an average rating of "Hold" and an average price target of $385.13.

UnitedHealth Group Stock Down 0.3%

Shares of UnitedHealth Group stock opened at $360.48 on Friday. The business's 50 day simple moving average is $337.26 and its 200 day simple moving average is $340.29. UnitedHealth Group Incorporated has a 52-week low of $234.60 and a 52-week high of $630.73. The firm has a market cap of $326.48 billion, a PE ratio of 15.62, a P/E/G ratio of 2.34 and a beta of 0.47. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.85 and a current ratio of 0.85.

UnitedHealth Group (NYSE:UNH - Get Free Report) last announced its earnings results on Tuesday, July 29th. The healthcare conglomerate reported $4.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.45 by ($0.37). UnitedHealth Group had a net margin of 5.04% and a return on equity of 23.32%. The firm had revenue of $111.62 billion during the quarter, compared to analyst estimates of $111.75 billion. During the same period in the prior year, the business posted $6.80 EPS. The firm's quarterly revenue was up 12.9% compared to the same quarter last year. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. On average, analysts predict that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current fiscal year.

UnitedHealth Group Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 23rd. Investors of record on Monday, September 15th were given a $2.21 dividend. This represents a $8.84 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Monday, September 15th. UnitedHealth Group's dividend payout ratio (DPR) is currently 38.30%.

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.